Non‐alcoholic fatty liver disease following liver transplantation: a clinical review. (11th August 2015)

• Record Type: Journal Article
• Authors: Merola, Jonathan; Liapakis, AnnMarie; Mulligan, David C.; Yoo, Peter S.
• Is Part Of: Clinical transplantation. Volume 29:Number 9(2015)
• Page Start: 728
• Page End: 737
• Publication Date: 2015-08-11
• Subjects: fatty liver disease -- non‐alcoholic steatohepatitis -- transplantation; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.12585
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: Non‐alcoholic steatohepatitis (NASH) is rapidly becoming the leading indication for liver transplantation (LT) in the United States. While post‐transplantation outcomes are similar to other indications for transplant, recent evidence has suggested that reduction in risk factors for post‐transplant metabolic syndrome may impose a significant survival benefit in this patient population. Cardiovascular mortality is the leading cause of death following transplantation for NASH. While pre‐transplant pharmacologic and surgical approaches have been utilized to reduce cardiovascular risk factors following transplantation, the effectiveness of these treatment approaches in the post‐transplant setting is poorly defined. Studies are urgently needed in the treatment of this rapidly growing population.